Results 131 to 140 of about 831 (147)

Raten an okkulten Neoplasien im Zusammenhang mit RRSO untersucht

Frauenheilkunde up2date, 2020
openaire   +2 more sources

Risk-Reducing Salpingo-Oophorectomy (RRSO) in BRCA Mutation Carriers

International Journal of Gynecological Cancer, 2011
C. Bethan Powell, Lee-may Chen, Jane McLennan, Beth Crawford, Charles Zaloudek, Joseph T. Rabban, Dan H. Moore, John Ziegler   +7 more
openaire   +1 more source

Hysterectomy during RRSO cost effective in BRCA1 carriers

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source

Occult cancers at risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers

Gynecologic Oncology, 2012
I. Cass, M. Zakhour, A. Walts, J. Gross, B. Karlan   +4 more
openaire   +1 more source

Serous Tubal Intraepithelial Carcinoma (STIC) and Precancerous Lesions in Risk-Reducing Salpingo-oophorectomy (RRSO) Specimens

2023
Kenta Masuda, Daisuke Aoki
openaire   +1 more source

RRSO for Aged Patients with Breast Cancer

Masayuki Sekine, Rie Nakamura, Tomoko Nakamoto, Yukiko Chinen, Yoshino Kinjo, Natsuki Tamashiro, Yuko Shimoji, Yusuke Taira, Yoshihisa Arakaki, Takuma Oyama, Wataru Kudaka   +10 more
openaire   +1 more source

Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers

Gynecologic Oncology, 2014
M. Zakhour, B.Y. Karlan, A.E. Walts, J. Gross, B.J. Rimel, C. Walsh, A.J. Li, I. Cass   +7 more
openaire   +1 more source

Primary peritoneal carcinoma surveillance practices following risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers

Gynecologic Oncology, 2016
E.N. Prendergast, M. Green, M. Zakhour, J. Lester, A.J. Li, C. Walsh, B.J. Rimel, R.S. Leuchter, B.Y. Karlan, I. Cass   +9 more
openaire   +1 more source

Surveillance and health outcomes for BRCA mutation carriers following risk-reducing salpingo-oophorectomy (RRSO)

Gynecologic Oncology, 2015
E. Prendergast, M. Green, M. Zakhour, J. Lester, A. Li, C. Walsh, B.J. Rimel, R. Leuchter, B. Karlan   +8 more
openaire   +1 more source

RRSO cost effective at ≥4% risk of ovarian cancer

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source